top of page

WORLD CONGRESS OF DERMATOLOGY, MILAN, 2019

  • Writer: ipharmaservices
    ipharmaservices
  • Jun 12, 2019
  • 1 min read

Updated: Jun 12, 2019

ABBVIE

Skyrizi

AbbVie has presented two-year data of Skyrizi (risankizumab) showing complete clearance in patients suffering from plaque psoriasis. Skyrizi is indicated for the treatment of plaque psoriasis in adults and has recently received the approval from European Medicines Agency.


About IMMhance study (Phase 3):

The drug was administered in two phases.

Results: 73% achieved skin clearance, 100% improvement in Psoriasis Area Severity Index was achieved in 72% patients compared to 2% of patients who withdrew the treatment.

Recent Posts

See All

Комментарии


For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code. 

Rephrase with Ginger (Cmd+⌥+E)
iPharmaCenter Telegran_edited.jpg
bottom of page